TR201908265T4 - Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. - Google Patents

Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. Download PDF

Info

Publication number
TR201908265T4
TR201908265T4 TR2019/08265T TR201908265T TR201908265T4 TR 201908265 T4 TR201908265 T4 TR 201908265T4 TR 2019/08265 T TR2019/08265 T TR 2019/08265T TR 201908265 T TR201908265 T TR 201908265T TR 201908265 T4 TR201908265 T4 TR 201908265T4
Authority
TR
Turkey
Prior art keywords
inhibitors
heat shock
dihydrodioxine
fused
derivatives
Prior art date
Application number
TR2019/08265T
Other languages
English (en)
Inventor
Jones Keith
Rye Carl
Chessum Nicola
Cheeseman Matthew
Elisa Pasqua Adele
Gordon Pike Kurt
Frank Faulder Paul
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of TR201908265T4 publication Critical patent/TR201908265T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, A1, A2 R4 ve Q?nun burada tanımlanan gibi olduğu formülün (I) bileşikleri ile ilgilidir. Mevcut buluş bileşikleri, ısı şok faktörü 1?in (HSF1) inhibitörleridir. Mevcut buluş özellikle, bu bileşiklerin kanser gibi proliferatif hastalıkların tedavisine ve/veya önlenmesine yönelik terapötik ajanlar olarak kullanımı ile ilgilidir. Mevcut buluş aynı zamanda, bu bileşiklerin hazırlanışına yönelik prosesler ve bunları içeren farmasötik bileşimler ile ilgilidir.
TR2019/08265T 2013-10-04 2014-10-03 Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. TR201908265T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317609.4A GB201317609D0 (en) 2013-10-04 2013-10-04 Inhibitor compounds

Publications (1)

Publication Number Publication Date
TR201908265T4 true TR201908265T4 (tr) 2019-06-21

Family

ID=49630211

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08265T TR201908265T4 (tr) 2013-10-04 2014-10-03 Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.

Country Status (20)

Country Link
US (5) US9701664B2 (tr)
EP (2) EP3521286B1 (tr)
JP (2) JP6500017B2 (tr)
KR (1) KR102332232B1 (tr)
CN (1) CN105814040B (tr)
AU (1) AU2014330940B2 (tr)
BR (1) BR112016007329B1 (tr)
CA (1) CA2925182C (tr)
DK (2) DK3052492T3 (tr)
ES (2) ES2730705T3 (tr)
GB (1) GB201317609D0 (tr)
IL (1) IL244452B (tr)
MX (1) MX369952B (tr)
PL (2) PL3052492T3 (tr)
PT (2) PT3052492T (tr)
RU (1) RU2671979C2 (tr)
SG (1) SG11201602547PA (tr)
TR (1) TR201908265T4 (tr)
WO (1) WO2015049535A1 (tr)
ZA (1) ZA201601223B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) * 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
WO2018162312A1 (en) 2017-03-10 2018-09-13 Basf Se Spirocyclic derivatives
WO2019043208A1 (en) * 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents
EP4045502A1 (de) 2019-10-17 2022-08-24 Bayer Aktiengesellschaft Photochemisches verfahren zur herstellung von (4r, 4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid
US20240398788A1 (en) * 2021-10-06 2024-12-05 Institute Of Cancer Research Methods of treating cancer using hsf1 pathway inhibitors
WO2023111005A1 (en) 2021-12-14 2023-06-22 Wmt Ag Carboxamide substituted heteroaromatic compounds for treating cancer
IL316122A (en) 2022-04-05 2024-12-01 Wmt Ag N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF LACTATE ATP PRODUCTION/FOR CANCER TREATMENT
EP4687903A1 (en) 2023-03-31 2026-02-11 Nuvectis Pharma, Inc. Methods of treating cancer using hsf1 pathway inhibitors

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137805A (en) 1988-03-18 1992-08-11 The General Hospital Corporation Method of diagnosing stress condition by specific binding of human heat shock factor
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
CA2096975C (en) 1990-11-26 2003-04-22 Carl Wu Cell stress transcriptional factors
DE19531321A1 (de) 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US7053052B2 (en) 1997-01-21 2006-05-30 Voellmy Richard W Therapies involving mutated heat shock transcription factor
US6281229B1 (en) * 1997-06-27 2001-08-28 Kaneka Corporation Heat shock factor activity inhibitors
US6268387B1 (en) 1997-12-23 2001-07-31 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
US6579872B1 (en) 1998-05-15 2003-06-17 Astrazeneca Ab Bezamide derivatives for the treatment of diseases mediated by cytokines
BR9912729A (pt) 1998-08-04 2001-05-02 Astrazeneca Ab Derivado de amida, processo para prepará-lo, e, uso do mesmo
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
DE60010448T2 (de) 1999-03-17 2005-04-07 Astrazeneca Ab Amid-derivate
EP1165092A1 (en) 1999-03-22 2002-01-02 Charterhouse Therapeutics Ltd. Cyclopentanone derivatives and their use
US6867036B1 (en) 1999-11-23 2005-03-15 Mayo Foundation For Medical Education And Research Gene expression by positive feedback activation of a cell type-specific promoter
US7405080B2 (en) 2000-03-23 2008-07-29 Voellmy Richard W Compositions and methods relating to prevention of chemotherapy-induced alopecia
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
JP2005504063A (ja) 2001-09-03 2005-02-10 リシャール・ヴェルミー 化学療法誘導性脱毛の予防に関連する組成物および方法
US20040122008A1 (en) 2002-09-05 2004-06-24 Protter Andrew A. Treatment of pain by inhibition of p38 MAP kinase
WO2004004703A1 (ja) 2002-07-04 2004-01-15 Mitsui Chemicals, Inc. メタフェニレンジアミン誘導体
EP1542699A4 (en) 2002-07-15 2009-03-25 Myriad Genetics Inc COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
GB0218260D0 (en) 2002-08-06 2002-09-11 Charterhouse Therapeutics Ltd Improvements in pharmaceutically useful compounds
US20050113450A1 (en) 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
EP1539121A4 (en) 2002-08-29 2008-08-13 Scios Inc METHOD OF REQUESTING OSTEOGENESIS
WO2004024083A2 (en) 2002-09-11 2004-03-25 University Of Medicine And Dentistry Of New Jersey Methods of bone healing
GB0223696D0 (en) 2002-10-14 2002-11-20 Ml Lab Plc Improved immunotherapy
US20060100245A1 (en) 2002-12-19 2006-05-11 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues
EP2316973A1 (en) 2003-06-10 2011-05-04 The Trustees Of Boston University Detection methods for disorders of the lung
US20070042997A1 (en) 2003-07-16 2007-02-22 Akiko Itai Medicament for treatment of dermal pigmentation
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
WO2005042496A1 (en) 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-benzyl-amine derivatives and methods for inhibiting heparanase activity
US7427390B2 (en) 2004-03-10 2008-09-23 Schering Ag Radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy
TW200616974A (en) 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
CA2583096A1 (en) * 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2007041294A2 (en) 2005-09-29 2007-04-12 The Trustees Of Boston University Methods for sensitizing cancer cells to inhibitors
EP1957461B1 (en) 2005-11-14 2016-11-02 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
EP1830289A1 (en) 2005-11-30 2007-09-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for hepatocellular carninoma classification and prognosis
US7919603B2 (en) 2005-12-19 2011-04-05 New York University Heat shock RNA
JP5296688B2 (ja) 2006-09-11 2013-09-25 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 殺虫化合物
WO2008079269A2 (en) 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
WO2008124096A1 (en) 2007-04-04 2008-10-16 Gaia Medical Institute Systems and methods for analyzing persistent homeostatic perturbations
CA2690569A1 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
JP2011506445A (ja) 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009137796A2 (en) 2008-05-08 2009-11-12 Northwestern University Method of regulating the heat shock response
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
US20110166038A1 (en) 2008-06-03 2011-07-07 Screening Methods For Heat-Shock Response Modulatiors Screening methods for heat-shock response modulators
CA2728674A1 (en) 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
UA38601U (en) * 2008-07-17 2009-01-12 Львовский Национальный Медицинский Университет Имени Данилы Галицкого 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity
EP2660596B1 (en) 2008-10-02 2018-06-13 Gaia Medical Institute Health test for a broad spectrum of health problems
JP2012505855A (ja) 2008-10-17 2012-03-08 ユニヴェルシテ リブレ ド ブリュッセル 抗癌治療における使用のためのジバニロイルおよびトリバニロイル誘導体
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
EP2367563A4 (en) 2008-12-08 2012-12-19 Univ Northwestern PROCESS FOR HSF-1 MODULATION
KR101699991B1 (ko) 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
KR101630432B1 (ko) 2009-08-28 2016-06-15 한국생명공학연구원 2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
MX339050B (es) 2009-12-18 2016-05-09 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
US20130133108A1 (en) 2010-08-25 2013-05-23 Katherine Warpeha Extracts from pirin+ and pirin- plants and uses thereof
EP2439194A1 (en) * 2010-10-05 2012-04-11 Rheinische Friedrich-Wilhelms Universität Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides
WO2012154858A1 (en) 2011-05-09 2012-11-15 Whitehead Institute For Biomedical Research Chaperone interaction assays and uses thereof
WO2013006495A2 (en) 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
US20160032284A1 (en) 2011-09-02 2016-02-04 Arrowhead Research Corportation Organic compositions to treat hsf1-related diseases
WO2013052888A1 (en) 2011-10-06 2013-04-11 Whitehead Institute For Biomedical Research Hsf 1 as a marker in tumor prognosis and treatment
WO2013166427A1 (en) 2012-05-03 2013-11-07 Whitehead Institute For Biomedical Research Hsf1 and hsf1 cancer signature set genes and uses relating thereto
KR101507221B1 (ko) 2012-05-14 2015-03-31 이화여자대학교 산학협력단 두충으로부터 분리된 화합물을 포함하는 열충격단백질 유도 활성을 갖는 조성물
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound

Also Published As

Publication number Publication date
US11787786B2 (en) 2023-10-17
CA2925182A1 (en) 2015-04-09
US11124501B2 (en) 2021-09-21
PL3052492T3 (pl) 2019-09-30
US20170037036A1 (en) 2017-02-09
JP6500017B2 (ja) 2019-04-10
JP2019135234A (ja) 2019-08-15
MX369952B (es) 2019-11-27
US10189821B2 (en) 2019-01-29
KR20160065950A (ko) 2016-06-09
AU2014330940A1 (en) 2016-03-03
US20190106413A1 (en) 2019-04-11
DK3521286T3 (da) 2021-12-06
MX2016004114A (es) 2016-06-06
US20240254110A1 (en) 2024-08-01
KR102332232B1 (ko) 2021-11-29
AU2014330940B2 (en) 2018-03-15
EP3052492A1 (en) 2016-08-10
CN105814040A (zh) 2016-07-27
BR112016007329A2 (pt) 2017-08-01
US20160289216A1 (en) 2016-10-06
HK1224285A1 (en) 2017-08-18
US20220220097A1 (en) 2022-07-14
RU2016117056A3 (tr) 2018-05-29
EP3052492B1 (en) 2019-03-27
ES2902124T3 (es) 2022-03-25
EP3521286B1 (en) 2021-09-29
JP6732071B2 (ja) 2020-07-29
ZA201601223B (en) 2020-08-26
SG11201602547PA (en) 2016-04-28
RU2671979C2 (ru) 2018-11-08
DK3052492T3 (da) 2019-05-06
GB201317609D0 (en) 2013-11-20
US9701664B2 (en) 2017-07-11
EP3521286A1 (en) 2019-08-07
PT3052492T (pt) 2019-06-27
PL3521286T3 (pl) 2022-03-21
CA2925182C (en) 2022-10-04
ES2730705T3 (es) 2019-11-12
PT3521286T (pt) 2021-12-30
WO2015049535A1 (en) 2015-04-09
IL244452B (en) 2020-06-30
JP2016531891A (ja) 2016-10-13
CN105814040B (zh) 2019-07-30
BR112016007329B1 (pt) 2021-02-02
IL244452A0 (en) 2016-04-21
RU2016117056A (ru) 2017-11-10

Similar Documents

Publication Publication Date Title
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
MX2016004114A (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1.
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX373324B (es) Compuestos piridínicos de pladienolida y métodos de uso.
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX382175B (es) Composiciones de profármaco de monometilfumarato
EA201990399A1 (ru) Соединения, композиции и их применение
EA201892539A1 (ru) Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
BR112015032262A2 (pt) composições de nanopartículas e formulações de compostos de piperazina
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.